The Fabry Disruption: How Gene Therapy Will Break a $1.7B ERT Monopoly

LAS VEGAS, NV – October 01, 2026 — For more than two decades, the commercial machinery of the rare disease sector has relied on a highly predictable, highly lucrative engine: the lifetime therapeutic tether. In conditions defined by missing or defective proteins, the standard of care has been to manufacture that missing element and infuse it directly into the patient on a rigid, recurring schedule. It is a model that guarantees steady revenue for pharmaceutical giants, but it exacts a heavy physical and psychological toll on patients.

Nowhere is the impending obsolescence of this model more visible than in the market for Fabry disease. A rare, inherited lysosomal storage disorder caused by a deficiency in the alpha-galactosidase A (α-Gal A) enzyme, Fabry disease leads to the toxic accumulation of lipids across multiple organ systems. For years, managing this accumulation has required bi-weekly intravenous enzyme replacement therapies (ERTs).

But the machinery is changing. According to a newly published outlook by market research firm DelveInsight, the Fabry disease landscape across the seven major global markets—valued at approximately $1.7 billion in 2025—is on the precipice of a radical transformation. Driven by a wave of advanced gene therapies and next-generation oral treatments, the market is shifting its focus from chronic management to durable, potentially curative interventions.

Disrupting a $1.7 Billion Monopoly

The current Fabry market is dominated by entrenched pharmaceutical heavyweights. Sanofi's Fabrazyme and Takeda's Replagal have long established the commercial baseline, while Chiesi's recently acquired Elfabrio represents an evolutionary step—a pegylated ERT designed for an extended half-life. These legacy treatments boast deep moats constructed from decades of real-world evidence, established physician networks, and complex payer agreements.

Yet, this monopoly is increasingly vulnerable to biotech challengers wielding entirely new modalities. The disruption is not merely clinical; it is fundamentally economic. The transition from recurring ERT revenue—which can cost healthcare systems hundreds of thousands of dollars annually per patient—to the "one-and-done" pricing model of gene therapies will force a structural realignment in how rare disease drugs are commercialized.

"ST-920 is a potential gene therapy in the development of Fabry disease, with its expected approval by Q2 2026 in the US," noted Aparna Thakur, Project Manager of Forecasting & Analytics at DelveInsight. Thakur added that among emerging oral therapies, "Idorsia Pharmaceuticals' Lucerastat is in the late stage of development, with its expected approval by 2030 in the US."

For incumbent ERT makers, the threat is existential. As gene therapies move toward commercialization, legacy pharmaceutical companies will be forced to defend their market share by emphasizing long-term safety records and pivoting their own pipelines. Meanwhile, health technology assessment (HTA) bodies, such as the Institute for Clinical and Economic Review (ICER), are already preparing to navigate the complex actuarial math required to evaluate multi-million-dollar upfront gene therapy price tags against a lifetime of ERT expenditures.

The End of the Bi-Weekly Infusion

At the vanguard of this paradigm shift is Sangamo Therapeutics with its investigational gene therapy, isaralgagene civaparvovec (ST-920). Utilizing a liver-tropic adeno-associated virus (AAV) vector, ST-920 is designed to deliver a functional copy of the GLA gene directly into the patient's liver cells, effectively turning the organ into an endogenous factory for the deficient α-Gal A enzyme.

The clinical data has been formidable. Presentations from the registrational Phase I/II STAAR study have consistently demonstrated that a single intravenous infusion of ST-920 can drive sustained, often supraphysiological levels of α-Gal A activity for years, alongside significant reductions in toxic substrate biomarkers.

Sangamo's aggressive posture underscores the high stakes. After regaining full global rights to the therapy following the termination of a partnership with Sanofi in mid-2024, Sangamo advanced a rolling Biologics License Application (BLA) to the FDA, completing the filing this past summer. If approved, ST-920 could be the first gene therapy to reach the Fabry market, offering patients a profound liberation from the clinical tether of bi-weekly infusions.

Following closely is uniQure's AMT-191, an AAV5-based gene therapy currently moving through Phase I/IIa trials. Like ST-920, AMT-191 aims for durable, single-administration efficacy. The success of these viral vector programs signals a broader maturation of gene therapy manufacturing and delivery, transitioning the technology from speculative science to a viable commercial product.

Targeted vs. Systemic: The Mechanism Battle

While gene therapies aim to replace the missing enzyme, a parallel battle is playing out over how to stop the toxic substrate from accumulating in the first place. Substrate reduction therapies (SRTs) are daily oral small molecules that inhibit glucosylceramide synthase (GCS), the enzyme responsible for producing the problematic lipids.

The appeal of SRTs lies in their convenience and their ability to bypass the immunogenicity issues that plague both ERTs and AAV gene therapies. However, the development of these molecules has revealed a deep pharmacological debate regarding targeted versus systemic efficacy.

Idorsia Pharmaceuticals is leading the peripheral SRT charge with lucerastat. The drug's path to market has required a strategic pivot. After its previous Phase III MODIFY study failed to meet a primary endpoint focused on neuropathic pain, Idorsia collaborated with the FDA to design the new ENVISION Phase III trial. Initiated in early 2026, ENVISION smartly shifts the primary endpoint to objective measures of kidney function, such as estimated glomerular filtration rate (eGFR). By focusing on organ protection rather than subjective pain scores, Idorsia aims to secure a 2030 approval for a drug that could serve as a highly convenient monotherapy or a combination agent with existing ERTs.

Similarly, AceLink Therapeutics is advancing AL1211, another peripheral GCS inhibitor that boasts excellent tissue penetration in the heart and kidneys—the primary organs compromised by Fabry disease. By intentionally limiting brain penetration, AceLink hopes to minimize off-target neurological side effects while aggressively clearing substrate from peripheral organs.

Conversely, the necessity of treating central nervous system manifestations in certain lysosomal storage disorders has kept CNS-penetrant drugs in the conversation. Although Sanofi previously halted the Fabry-specific development of its CNS-penetrant GCS inhibitor, venglustat, due to missed endpoints, the broader scientific debate regarding the necessity of crossing the blood-brain barrier remains a critical point of contention for next-generation pipeline assets.

Finally, occupying a unique middle ground is Glafabra Therapeutics' GT-GLA-S03. This autologous cell therapy genetically modifies a patient's own cells to express the enzyme. Because it avoids the use of a viral capsid, GT-GLA-S03 circumvents the pre-existing neutralizing antibodies that render roughly 40% of adults ineligible for AAV gene therapies. Furthermore, unlike one-time AAV treatments, Glafabra's therapy is designed to be re-dosable if enzyme expression eventually wanes.

The evolution of the Fabry disease market is a microcosm of the modern biotechnology landscape. It is a space where the blunt force of legacy commercial monopolies is finally meeting the precise, disruptive power of genomic medicine and advanced pharmacology. For the investors funding these clinical trials, the regulatory bodies assessing their merits, and the patients waiting for relief, the next decade will not merely introduce new products; it will fundamentally rewrite the economic and clinical rules of rare disease management.